Genome architecture mapping

Patent metadata

Field	Value
Publication number	US-10526639-B2
Application number	US-201515533890-A
Country	US
Kind code	B2
Filing date	Dec 11, 2015
Priority date	Dec 11, 2014
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

The present invention relates to the field of analysis of the three-dimensional structure of the genome, i.e., for genome architecture mapping (GAM). The invention provides a method of determining spatial proximity of a plurality of nucleic acid loci in a compartment such as the cell nucleus, by exploiting their co-segregation amongst fractions of that compartment, identified upon separation of the nucleic acid loci from each other depending on their localization in the compartment to obtain a collection of fractions, e.g., by cryo-sectioning or cryo-milling the compartment; determining the presence or absence of the plurality of loci in the fractions; and determining the co-segregation of the plurality of loci. Co-segregation may then be analysed with statistical methods to determine spatial proximity. The method can be used e.g., for determining physical distance between a plurality of loci; and mapping loci and/or genome architecture, e.g., in the nucleus; identification of regulatory regions directing expression of a specific gene through spatial contacts; identifying the nuclear position of an exogenous nucleic acid in the nucleus and/or diagnosing a disease associated with a disturbed co-segregation of loci.

First claim

The invention claimed is:

1. A method of determining spatial proximity of a plurality of nucleic acid loci in a cellular compartment comprising nucleic acids, wherein the cellular compartment is derived from a cell or is a prokaryotic cell, comprising:
(a) cryosectioning a plurality of cellular compartments to obtain a collection of fractions comprising more than 180 fractions each having a thickness of 70 nm to 1000 nm, thereby separating nucleic acid loci from each other depending on their location in one or more of the cellular compartments;
(b) determining the presence or absence of the plurality of loci in said fractions by sequencing; and
(c) determining co-segregation of said plurality of loci, wherein spatial proximity is determined by analysing co-segregation with an inferential statistical method,
wherein the method does not comprise restriction digest of nucleic acids in combination with ligation between nucleic acids originally present in the compartment.

2. The method of claim 1 , wherein the nucleic acids are DNA and/or RNA.

3. The method of claim 1 , wherein the compartment is a nucleus of an eukaryotic cell, a mitochondrion or a prokaryotic cell.

4. The method of claim 1 , wherein step (a) is preceded by cross-linking with formaldehyde.

5. The method of claim 1 , wherein the separation in step (a) is carried out by ultracryosectioning the compartment.

6. The method of claim 1 , wherein one compartment is separated into about 5-300 fractions.

7. The method of claim 1 , wherein the plurality of loci is two loci to all nucleic acid loci in the compartment.

8. The method of claim 1 , wherein the method allows for detection of at least three co-segregating loci.

9. The method of claim 1 , wherein the presence or absence of the plurality of loci is determined by next generation sequencing.

10. The method of claim 1 , wherein loci are determined to be proximal in space when they co-segregate at a frequency higher than expected from their linear genomic distance on a chromosome.

11. The method of claim 1 , wherein the compartment is an eukaryotic nucleus and single nuclear profiles are isolated from sections.

12. The method of claim 1 , wherein the nucleic acids are DNA.

13. The method of claim 1 , wherein the cell is selected from the group consisting of a bacterium, a protozoan, a plant cell, a fungal cell, and a mammalian cell.

14. The method of claim 13 , wherein the cell is a human cell.

15. The method of claim 13 , wherein the cell is a cell of a human patient having a disease or disorder.

16. The method of claim 1 , wherein the cellular compartment or the cell or a tissues or whole organisms comprising the cellular compartment or the cell is treated with a crosslinking agent before step (a) is carried out.

17. The method of claim 1 , wherein cellular ultrastructure is preserved by vitrification.

Assignees

• Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft
• Cambridge Entpr Ltd

Inventors

• Pombo Ana
• Edwards Paul
• Nicodemi Mario
• Scialdone Antonio
• Beagrie Robert

Classifications

• G16B20/00

  ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations · CPC title

• C12Q1/68 Primary

  involving nucleic acids · CPC title

• C12N15/1003 Primary

  Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor · CPC title

• C12Q2523/101

  Crosslinking agents, e.g. psoralen · CPC title

• C12Q2565/133

  conformational analysis · CPC title